P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 9.7 SEK -1.02% Market Closed
Market Cap: 49.9m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Wall Street
Price Targets

PROGEN Price Targets Summary
Prostatype Genomics AB

There are no price targets for PROGEN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Prostatype Genomics AB Competitors:
Price Targets
BPMC
Blueprint Medicines Corp
34% Upside
NIOX
Niox Group PLC
31% Upside
SGMT
Sagimet Biosciences Inc
460% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
14% Downside
214450
PharmaResearch Co Ltd
23% Upside
DNLI
Denali Therapeutics Inc
39% Upside
688105
Nanjing Vazyme Biotech Co Ltd
17% Downside
VICO
Vicore Pharma Holding AB
270% Upside

Revenue
Forecast

Revenue Estimate
Prostatype Genomics AB

For the last 7 years the compound annual growth rate for Prostatype Genomics AB's revenue is 56%. The projected CAGR for the next 2 years is 546%.

56%
Past Growth
546%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Prostatype Genomics AB

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Prostatype Genomics AB

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PROGEN's stock price target?
Not Available

PROGEN doesn't have any price targets made by Wall Street professionals.

What is Prostatype Genomics AB's Revenue forecast?
Projected CAGR
546%

For the last 7 years the compound annual growth rate for Prostatype Genomics AB's revenue is 56%. The projected CAGR for the next 2 years is 546%.

Back to Top